Table 8

Extended endocrine therapy

StudyTrial nameSettingPrimary outcomeMedian follow-upDFS controlDFS gain (%)DFS HR*OS controlOS gain (%)OS HR*ESM0-MCBS V.1.1Reference
Letrozole 5 years vs placeboMA-17Postmenopausal HR+ after 5 years tamoxifen (all)DFS30 months89.8%4.60.58 (0.45–0.76)95.0%0.40.82 (0.57–1.19)A65 66
Letrozole 5 years vs placeboMA-17Postmenopausal HR+ after 5 years tamoxifen (Node+)DFS30 months0.61 (0.45–0.84)0.61 (0.38–0.98)A65 66
Letrozole 5 years vs placeboMA-17RPostmenopausal HR+ after 5 years tamoxifenDFS6.3 years91.0%4.00.66 (0.48–0.91)94.0%1.00.97 (0.73–1.28)NEB67
Anastrozole for 3 years vs placeboABCSG6aPostmenopausal HR+ after 5 years tamoxifenRFS>5 years7.1%4.70.62 (0.40–0.96)88.3%1.40.98 (0.59–1.34)NEB68
Exemestane vs placeboNSABP-B33Postmenopausal HR+ after 5 years tamoxifenDFS30 months89.0%2.00.68 p=0.07NEB69
TamoxifenATLASPostmenopausal HR+ after 5 years tamoxifenBC recurrence and BC mortality7.6 yearsRisk of recurrence at ≥10 years 25.1%3.70.75 (0.62–0.90)BC mortality 15%2.80.71 (0.58–0.88)C70
  • Chart blanks—relevant variables not available in manuscript.

  • *HR values in parentheses refer to 95% CI.

  • BC, breast cancer; DFS, disease-free survival; ESMO-MCBS, The European Society for Medical Oncology-Magnitude of Clinical Benefit Scale; HR+, hormone receptor-positive; NEB, no evaluable benefit; Node+, node-positive; OS, overall survival; RFS, relapse free survival.